|
|
RICT 2009 - Drug Discovery and Selection |
| Biophysics Tools and ADME Tox |
03/07/2009
14:00 | Biophysical Approaches in the Hit-to-Lead Optimisation Strategy |
Dr. Jean BOUTIN
(INSTITUT DE RECHERCHES SERVIER, Croissy-sur-Seine, France) |
03/07/2009
14:45 | ADME-PK Optimization Strategies in Drug Discovery and Selection |
Dr. Sonia POLI
(ADDEX PHARMA, Plan-les-Ouates, Switzerland) |
| From Target Identification to Development |
01/07/2009
11:00 | The Therapeutic Potential of Pharmacological Inhibitors of Cyclin-Dependent Kinases |
Dr Laurent MEIJER
(CNRS - ROSCOFF, Roscoff, France) |
01/07/2009
11:45 | Targeted Small Molecule Anti-Cancer Drugs: an Asian Perspective from Discovery to Clinical |
Dr. Stéphanie BLANCHARD
(S*BIO, Singapore, Singapore) |
01/07/2009
14:30 | Selective Inhibitors of MMP-12 : from Chemistry to Therapeutic Applications |
Dr. Vincent DIVE
(CEA, Gif-sur-Yvette, France) |
01/07/2009
15:15 | Discovery of the Macrocyclic HCV Protease Inhibitor TMC435350 |
Dr Pierre RABOISSON
(JANSSEN PHARMACEUTICAL COMPANIES, Beerse, Belgium) |
01/07/2009
16:30 | Irreversible Serine Protease Inhibitors: Useful Tools in Drug Discovery |
Prof. Koen AUGUSTYNS
(UNIVERSITY OF ANTWERP, Antwerp, Belgium) |
01/07/2009
17:15 | « Paul Ehrlich» Lecture: Discovery of Xarelto, a Novel, Oral Antithrombotic Agent |
Dr. Susanne ROEHRIG
(BAYER SCHERING PHARMA, Wuppertal, Germany) |
| High Throughput Screening and Lead Identification |
02/07/2009
14:00 | Generation of New Active Compounds in an Industrial-Academic Screening
Organization |
Dr. Frederic AUSSEIL
(INSTITUT DE RECHERCHE PIERRE FABRE, Toulouse, France) |
02/07/2009
14:45 | New Strategies in Chemical Biology : Scientific and Therapeutic Outcome |
Prof. Marcel HIBERT
(UNIVERSITÉ DE STRASBOURG, Illkirch, France) |
02/07/2009
15:30 | The Crystal Structure of the Adenosine A2A Receptor - Implications for GPCR Drug Design |
Prof. Ad P. IJZERMAN
(UNIVERSITY OF LEIDEN, Leiden, The Netherlands) |
02/07/2009
17:00 | Aptamers: Oligonucleotides that Rival Antibodies for Therapeutics and Diagnostics. |
Prof. Jean-Jacques TOULME
(IECB & INSERM - UNIVERSITÉ BORDEAUX II, Bordeaux, France) |
02/07/2009
17:45 | Recent Developments in Structural Biology: Applying Crystallographic and NMR Approaches in Lead Finding and Optimization |
Dr Vincent MIKOL
(SANOFI AVENTIS, Vitry-sur-Seine, France) |
| Imaging |
02/07/2009
08:30 | Facilitating Drug Development with PET Imaging |
Dr Yves P. AUBERSON
(, Basel, Switzerland) |
02/07/2009
09:15 | Targeting G-Protein Coupled Receptors with Radiolabeled Peptides for the Molecular Imaging and Targeted Therapy of Cancer |
Dr. Helmut MAECKE
(UNIVERSITY HOSPITAL, Basel, Switzerland) |
02/07/2009
10:30 | PET Imaging in Drug Discovery and Development of CNS Drugs |
Dr. Jose Ignacio ANDRES
(JOHNSON & JOHNSON PHARMACEUTICAL R & D, Toledo, Spain) |
02/07/2009
11:15 | Modified Selective Integrin Ligands for Cancer Therapy, Molecular Imaging and for Improvement of Biomaterials |
Dr Horst KESSLER
(TECHNISCHE UNIVERSITÄT MÜNCHEN, Garching, Germany) |
| In Silico Selection |
01/07/2009
09:30 | Navigation in Chemistry Universe Towards Biological
Activity
|
Dr Peter ERTL
(NOVARTIS INSTITUTE FOR BIOMEDICAL RESEARCH, Basel, Switzerland) |
01/07/2009
10:15 | Structure-Based in Silico Screening: Free Tools and Applications |
Dr. Bruno VILLOUTREIX
(INSERM - UNIVERSITY PARIS DIDEROT, Paris, France) |
| Interfacing Chembio and MedChem |
02/07/2009
08:30 | GLP-1 Analog Taspoglutide: Design, Synthesis and Biological Activity |
Dr. Jesse DONG
(IPSEN, Milford, United States) |
02/07/2009
09:15 | Experiences in Fragment Based Lead Discovery |
Prof. Rod HUBBARD
(UNIVERSITY OF YORK / VERNALIS, York, United Kingdom) |
02/07/2009
10:30 | Using Knowledge from NBEs to Inform Drug Design |
Dr. Alastair LAWSON
(UCB CELLTECH, Slough, United Kingdom) |
02/07/2009
11:15 | Diversity Oriented Synthesis of Natural Product Motifs |
Prof. Nicolas WINSSINGER
(UNIVERSITY OF STRASBOURG, Strasbourg, France) |
| Synthesis and Lead Optimization |
02/07/2009
14:00 | Discovery of Potent, Selective and Orally Bioavailable DP2 Receptor Antagonists for the Treatment of Allergic Inflammatory Diseases |
Dr. Stefano CROSIGNANI
(MERCK-SERONO PHARMACEUTICAL RESEARCH INSTITUTE, Plan-les-Ouates, Switzerland) |
02/07/2009
14:45 | Dynamic Combinatorial Chemistry in Chemical Biology and Drug Discovery |
Prof. Jean-Marie BEAU
(UNIVERSITÉ PARIS SUD 11, Orsay, France) |
02/07/2009
15:30 | Development of Marine Anticancer Drugs |
Dr. Andrès FRANCESCH
(PHARMAMAR, Colmenar Viejo, Spain) |
02/07/2009
17:00 | A Chemistry-Driven Approach to the Discovery of New Calcium-Sensing Receptor Ligands and Antimitotic Agents |
Dr. Robert H. DODD
(ICSN CNRS, Gif-Sur-Yvette, France) |
02/07/2009
17:45 | Knowledge management, prospective design and chemical enablement as strategies for lead optimization: The PDE-9 inhibitor and opiate antagonist case studies. |
Dr. Spiros LIRAS
(PFIZER GLOBAL RESEARCH, Groton, United States) |
03/07/2009
09:00 | Taking up the Adme Challenge
|
Prof. Benoit DEPREZ
(UNIVERSITY OF LILLE 2, Lille, France) |
03/07/2009
09:45 | Discovery of Novel Potent, Selective and Orally Efficacious A2B Adenosine Receptor Antagonists. |
Dr. Bernat VIDAL
(LABORATORIOS ALMIRALL, Barcelona, Spain) |
03/07/2009
11:00 | New Synthetic Methods and their Application to the Preparation of Biologically Active Molecules |
Prof. Mike SHIPMAN
(UNIVERSITY OF WARWICK, Coventry, United Kingdom) |
03/07/2009
11:45 | « Prix Charles Mentzer »: From Heparin to New Anticoagulants with Unprecedented Pharmacological Profile |
Dr. Maurice PETITOU
(ENDOTIS PHARMA, Romainville, France) |
| <Previous page |
